US Flag logoAn official website of the United States government
Acute Lymphoblastic Leukemia (ALL) Expansion Phase 2 and Acute Leukemias of Ambiguous Lineage (ALAL) Phase 3
TARGET
Data Resource:  TARGET
Point of Contact:  
Center for Cancer Genomics,  
Project

About This Dataset
In the expansion effort (Phase 2), TARGET investigators analyzed tumors from pediatric patients, most who experienced an early bone marrow relapse (within 4 years of initial diagnosis), to identify new therapeutic approaches and/or biomarkers that correlate with poor clinical outcome to treat childhood pre-cursor B-cell ALL. The tissues used in this study were collected from patients enrolled in Children's Oncology Group (COG) biology studies and clinical trials. For Phase 3, leukemia can arise from distinct lineages of blood cells, either lymphoid or myeloid. On occasion, patients present with an acute leukemia for which a specific lineage cannot be clearly determined. These cases are classified as acute leukemias of ambiguous lineage (ALAL) and account for less than 4% of all acute leukemias across age groups. TARGET investigators at St. Jude Children's Research Hospital led an effort to better understand ALAL. The TARGET initiative contributed to this key study by characterizing ~50 ALAL cases.
Core Data Elements
Number of Cases
1,701
Case Sex
Female (614); Male (763); Not Reported (324)
Case Age At Diagnosis
0 to 4 years (561); 5 to 9 years (280); 10 to 14 years (328); 15 to 19 years (194); 20 to 24 years (12); 25 to 29 years (2); Pediatric and Young Adult (<40 years) (324)
Case Race
American Indian or Alaska Native (4); Asian (68); Black or African American (111); Native Hawaiian or Other Pacific Islander (7); White (1,186); Not Reported (230); Unknown (95)
Case Ethnicity
Hispanic or Latino (382); Not Hispanic or Latino (1,105); Not Reported (119); Unknown (95)
Case Disease Diagnosis
Acute Leukemias of Ambiguous Lineage (115); Acute Lymphoblastic Leukemia, NOS (1,586)
Case Tumor Site
Blood (1,701)
Additional Data Elements
DBGAP STUDY IDENTIFIER
DATA REPOSITORY
Grant Information
261200800001E-12-0-40
Therapeutically Applicable Research to Generate Effective Treatments (TARGET)
HHSN261200800001E
NCI Contract
U10CA180886
COG NCTN Network Group Operations Center
Published In
https://www.cancer.gov/ccg/research/genome-sequencing/target/publications?field_publication_project_target_id_selective=18&items_per_page=10#acute-lymphoblastic-leukemia-allnbsp
Charts
Male (763); Female (614); Not Reported (324)
763Male